SCHEMBL6946347

SCHEMBL6946347

CCCC1(CCC)CCC2(CC1)CC(=O)OC(=O)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6944961 0.84 KDM4E (0.30)
SCHEMBL286913 0.78 TSHR (0.42)
SCHEMBL5858279 0.71 GABRP (0.37)
SCHEMBL29324533 0.71
SCHEMBL9430138 0.69 PRKCA (0.36)
SCHEMBL2761366 0.69 TSHR (0.38)
SCHEMBL194872 0.69 TSHR (0.38)
SCHEMBL2915774 0.68 TSHR (0.47)
SCHEMBL9396969 0.68 SIRT2 (0.39)
SCHEMBL13593724 0.68 CYP1A2 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0587800-B1 IMMUNOMODULATORY AZASPIRANES ANORMED INC (CA) 2003-04-02 EP disclosed
EP-0654997-A4 COMPOSITIONS OF SUBSTITUTED AZASPIRANES AND METHODS OF TREATING PSORIASIS THEREWITH. SMITHKLINE BEECHAM CORP (US) 1997-09-17 EP disclosed
EP-0771199-A1 METHODS SMITHKLINE BEECHAM CORPORATION (US) 1997-05-07 EP disclosed
US-5591748-A Immunomodulatory azaspiranes SMITHKLINE BEECHAM CORPORATION (US) 1997-01-07 US disclosed
WO-1996003123-A1 METHODS SMITHKLINE BEECHAM CORPORATION (US) 1996-02-08 WO disclosed
US-5455247-A Methods for the treatment of hyperlipidemia using azaspiranes SMITHKLINE BEECHAM CORPORATION (US) 1995-10-03 US disclosed
EP-0654997-A1 COMPOSITIONS OF SUBSTITUTED AZASPIRANES AND METHODS OF TREATING PSORIASIS THEREWITH SMITHKLINE BEECHAM CORPORATION (US) 1995-05-31 EP disclosed
WO-1995003048-A1 ANTI-HIV AZASPIRANES SMITHKLINE BEECHAM CORPORATION (US) 1995-02-02 WO disclosed
WO-1995003046-A1 A METHOD OF INHIBITING THE PRODUCTION OF HIV SMITHKLINE BEECHAM CORPORATION (US) 1995-02-02 WO disclosed
WO-1995003047-A1 HUMAN IMMUNODEFICIENCY VIRUS TREATMENTS SMITHKLINE BEECHAM CORPORATION (US) 1995-02-02 WO disclosed
EP-0310321-B1 Immunomodulatory azaspiranes SMITHKLINE BEECHAM CORP (US) 1994-11-30 EP disclosed
EP-0609335-A4 METHODS FOR THE TREATMENT OF HYPERLIPIDEMIA USING AZASPIRANES. SMITHKLINE BEECHAM CORP (US) 1994-10-12 EP disclosed
EP-0609335-A1 METHODS FOR THE TREATMENT OF HYPERLIPIDEMIA USING AZASPIRANES SMITHKLINE BEECHAM CORPORATION (US) 1994-08-10 EP disclosed
WO-1994004151-A1 COMPOSITIONS OF SUBSTITUTED AZASPIRANES AND METHODS OF TREATING PSORIASIS THEREWITH SMITHKLINE BEECHAM CORPORATION (US) 1994-03-03 WO disclosed
WO-1993015735-A1 (NON DESCRIPTIVE)-A METHOD FOR DELAYING HIV INDIVIDUAL AIDS BY ADMINISTRATION OF SUBSTITUTED AZASPIRANE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1993-08-19 WO disclosed
WO-1993007871-A1 METHODS FOR THE TREATMENT OF HYPERLIPIDEMIA USING AZASPIRANES SMITHKLINE BEECHAM CORPORATION (US) 1993-04-29 WO disclosed
WO-1992022294-A1 IMMUNOMODULATORY AZASPIRANES SMITHKLINE BEECHAM CORPORATION (US) 1992-12-23 WO disclosed
EP-0310321-A2 Immunomodulatory azaspiranes SMITHKLINE BEECHAM CORPORATION (US) 1989-04-05 EP disclosed